About Adapsyn
Adapsyn is a company based in Hamilton (United States) founded in 2016 by Nathan Magarvey. Adapsyn offers products and services including Genomics Platform, Metabolomics Platform, and Assay Biology Platform. Adapsyn operates in a competitive market with competitors including Evelo Biosciences, Kallyope, PathogenDX, Manus Bio and Newcells Biotech, among others.
- Headquarter Hamilton, United States
- Founders Nathan Magarvey
- SectorsHealthcare
- Email••••••••
- Website adapsyn.com
- Social LinkedIn
- Legal Name Adapsyn Bioscience Inc
- InvestorsGates Foundation
& 2 more
Products & Services of Adapsyn
Adapsyn offers a comprehensive portfolio of products and services, including Genomics Platform, Metabolomics Platform, and Assay Biology Platform.
Identifies microbial strains for novel chemistry and drug prediction.
Detects compounds from microbes for evaluation and isolation.
Generates chemical libraries for screening and biochemical assays.
Funding Insights of Adapsyn
- Total Rounds 2
- Investors Count 3
All 2 funding rounds of Adapsyn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | – | Grant | – | – | |
| Jan 2018 | – | Seed | – | – |
3 investors in total: 3 institutional.
Investors in Adapsyn
Adapsyn has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Genesys Capital and Pfizer Venture Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage life sciences companies are supported through venture capital investments. | – | genesyscapital.com | Toronto, Canada | |
Venture capital is focused on healthcare by Pfizer's investment arm. | – | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Adapsyn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adapsyn
9 people are tracked at Adapsyn (6 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Nathan Magarvey | Founder | Leadership |
Andy Haigh | President, CEO & Board Member | Leadership |
Chris Dejong | VP of Technology | Leadership |
Dan Wallace | Director of Technology | Leadership |
David Earl | Director of Chemical Biology | Leadership |
Dave Capstick | Director of Operations | Leadership |
Christopher O’Donnell | Board Member | Board & advisors |
Kelly Holman | Board Member | Board & advisors |
Lloyd Mackenzie | Board Member | Board & advisors |
Complete people profiles for Adapsyn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adapsyn
3 dated milestones of Adapsyn across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Adapsyn is founded.
- Funding First funding round.
- Funding Latest funding round, Grant,.
Competitors of Adapsyn
Adapsyn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evelo Biosciences, Kallyope, PathogenDX, Manus Bio and Newcells Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| kallyope.com | 2014 | New York, United States | $479M | 84 | The gut-brain axis is explored for therapeutic and nutritional innovations. | |
| pathogendx.com | 2014 | Tucson, United States | $11.58M | 31 | Provider of DNA-based pathogen testing kits | |
| manusbio.com | 2011 | Cambridge, United States | $115.93M | – | Phytochemicals are developed using microbial fermentation processes. | |
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| insphero.com | 2009 | Schlieren, Switzerland | $35.02M | – | Cell-based assays and 3D microtissues for drug screening are developed. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| oxthera.com | 2005 | Stockholm, Sweden | $93.1M | – | Microbial-based drug products for hyperoxaluria treatment are developed. | |
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | – | Developer of AI-based platform for lab-grown human tissues | |
| biocortex.com | 2021 | London, United Kingdom | $5M | – | Human-microbiome platform is developed for drug discovery applications. |
Detailed competitors of Adapsyn
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adapsyn
Complete news archive for Adapsyn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Adapsyn
10 companies that operate in the same segment as Adapsyn (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adapsyn
Adapsyn was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Adapsyn is headquartered in Hamilton, United States.
Adapsyn was founded in 2016 in Hamilton, United States. Computational tools are offered for bacterial metabolomic and genomic data analysis within the biotechnology sector. Proprietary machine learning is applied to microbial data to identify natural products encoded in genomes. Technology platforms such as PRISM, GARLIC, GRAPE, CLAMS, and ADAPSYN GRAPH are utilized for artificial intelligence in natural product drug discovery.
Adapsyn's top competitors include PathogenDX, Manus Bio and Newcells Biotech.
Adapsyn offers Genomics Platform, Metabolomics Platform, and Assay Biology Platform.
Adapsyn has 3 investors. Key investors include Gates Foundation, Genesys Capital, and Pfizer Venture Investments.
Adapsyn operates through Adapsyn Bioscience Inc.